Jaguar Health Announces Approval of Proposals at Special Stockholders Meeting

Jaguar Health, Inc. has announced that all six proposals submitted were approved at the November 6, 2026 Special Meeting of Stockholders. The meeting took place in San Francisco, California, and saw a favorable response from the company’s shareholders.

The detailed proposals are outlined in Jaguar's definitive proxy statement, which was filed with the Securities and Exchange Commission (SEC) on October 8, 2026. Additional information was provided in supplemental forms. Interested parties can access these documents at the SEC's website or Jaguar's corporate site.

Jaguar Health focuses on the development of proprietary prescription drugs sourced from plants, addressing gastrointestinal diseases. Their affiliates, Napo Pharmaceuticals and Napo Therapeutics, commercialize treatments for rare disorders, while Magdalena Biosciences explores plant-derived mental health medications.